Morgan DA , Ruscetti FW , Gallo RG . Selective in vitro growth of T-lymphocytes from normal bone marrows. Science. 1976;193:1007–8. [PubMed: 181845]

Paul WE , Seder RA . Lymphocyte responses and cytokines. Cell. 1994;76:241–51. [PubMed: 7904900]

Zeh HJ , Hurd S , Storkus WJ . et al. Interleukin 12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother. 1993;14:155–61. [PubMed: 7904180]

Kondo M , Takeshita T , Ishii N . et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 1993;262:1874–7. [PubMed: 8266076]

Takeshita T , Asao H , Ohtani K . et al. Cloning of the gamma chain of the human IL-2 receptor. Science. 1992;257:379–82. [PubMed: 1631559]

Wang H-M , Smith KA . The interleukin-2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987;166:1055–69. [PMC free article: PMC2188729] [PubMed: 3116143]

Stern JB , Smith KA . Interleukin-2 induction of T-cell G₁ progression and c-myb expression. Science. 1986;233:203–6. [PubMed: 3523754]

Yang SC , Grimm EA , Parkinson DR . et al. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small-cell lung cancer: a phase I trial. Cancer Res. 1991;51:3669–76. [PubMed: 1648441]

Yang SC , Owen-Schaub LB , Grimm EA , Roth JA . Induction of lymphokine activated killer cytotoxicity with interleukin-2 and tumor necrosis factor alpha against primary lung cancer target. Cancer Immunol Immunother. 1989;29:193–6. [PubMed: 2543502]

Grimm EA , Mazumder A , Zhang HZ , Rosenberg SA . The lymphokine-activated killer cell phenomenon: lysis of NK-resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–41. [PMC free article: PMC2186695] [PubMed: 6176669]

Mier JW , Vachino G , Van Der Meer JWM . et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. 1988;8:426–36. [PubMed: 3265420]

Owen-Schaub LB , de Mars M , Murphy EO Jr, Grimm EA . IL-2 dose regulates TNF-a mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cell Immunol. 1991;132:193–200. [PubMed: 2065356]

Abrams JS , Rayner AA , Wiernik PH . et al. High-dose recombinant interleukin-2 alone. J Natl Cancer Inst. 1990;82:1202–6. [PubMed: 2194036]

Atkins MB , Sparano J , Fisher RI . et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993;11:661–70. [PubMed: 8478661]

McCabe MS , Stablein D , Hawkins MJ . The Modified Group C experience: Phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol. 1991;10:213.

Rosenberg SA . Karnofsky Memorial Lecture: the immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10:180–99. [PubMed: 1732421]

Rosenberg SA , Lotze MT , Muul LM . et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose, interleukin-2 alone. N Engl J Med. 1987;316:889–97. [PubMed: 3493432]

Rosenberg SA , Lotze MT , Muul LM . et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–92. [PubMed: 3903508]

Rosenberg SA , Lotze MT , Yang JC . et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474–85. [PMC free article: PMC1357927] [PubMed: 2679456]

Rosenberg SA , Lotze MT , Yang JC . et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622–32. [PubMed: 8468720]

Fyfe G , Fisher R , Rosenberg SA . et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–96. [PubMed: 7884429]

Geertsen PF , Hermann GG , von der Maase H . et al. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. J Clin Oncol. 1992;10:753–9. [PubMed: 1569448]

Parkinson DR , Sznol M . High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Semin Oncol. 1995;22:61–6. [PubMed: 7855620]

Boldt DH , Mills BJ , Gemlo BT . et al. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res. 1988;48:4409–16. [PubMed: 3260537]

Palmer PA , Vinke J , Philip T . et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992;3:475–80. [PubMed: 1498066]

Blay JY , Favrot MC , Negrier S . et al. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res. 1990;50:2371–4. [PubMed: 2317822]

Walther MM , Alexander RB , Weiss GH . et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology. 1993;42:250–8. [PubMed: 8379024]

Fleischmann JD , Kim B . Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol. 1991;145:938–41. [PubMed: 2016805]

Sznol M , Parkinson D . Clinical applications of IL-12. Oncology. 1994;8:61–7. [PubMed: 7521197]

Sznol M, Thurn A, Parkinson DR. Overview of interleukin-2 trials in patients with renal cell carcinoma. In: Bukowski R, editor. Immunobiology of renal carcinoma. New York: Marcel Dekker; 1993.

Wagstaff J , Baars JW , Wolbink GJ . et al. Renal cell carcinoma and interleukin-2: a review. Eur J Cancer. 1995;31A:401–8. [PubMed: 7540404]

Bukowski RM . Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80:1198–220. [PubMed: 9317170]

Jayson GC , Middleton M , Lee SM . et al. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer. 1998;78:366–9. [PMC free article: PMC2063040] [PubMed: 9703284]

Strohmaier WL . New treatment modalities—the urologist's view. Anticancer Res. 1999;19:1605–9. [PubMed: 10365155]

Dutcher JP , Gaynor ER , Boldt DH . et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol. 1991;9:641–8. [PubMed: 2066760]

Parkinson DR , Abrams JS , Wiernik PH . et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 1990;8:1650–6. [PubMed: 2213101]

Keilholz U , Conradt C , Legha SS . et al. Results of interleukin-2 based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998;16:2921–9. [PubMed: 9738559]

Atkins MB , O'Boyle K , Sosman J . et al. A multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol. 1993;12:394. [PubMed: 8040667]

Buzaid AC , Legha SS . Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of advanced melanoma. Semin Oncol. 1994;21:23–8. [PubMed: 7992096]

Khayat D , Borel C , Tourani JM . et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alpha-2 for metastatic melanoma. J Clin Oncol. 1993;11:2173–80. [PubMed: 8229131]

Legha S , Plager C , Ring S . et al. A phase II study of biochemotherapy using interleukin-2 (IL-2) 1 interferon alpha-1A (IFN) in combination with cisplatin (C), vinblastine (V), and DTIC (D) in patients with metastatic melanoma. Proc Am Soc Clin Oncol. 1992;11:343.

Richards JM , Mehta N , Ramming K . et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10:1338–43. [PubMed: 1634924]

Keiholz U , Stoter G , Punt CJ . et al. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am. 1997;3:22–8. [PubMed: 9457389]

Rosenberg SA , Yang JC , Schwartzentruber DJ . et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol. 1999;163:1690–5. [PMC free article: PMC2249693] [PubMed: 10415076]

Kaplan G , Britton WJ , Hancock GE . et al. The systemic influence of recombinant interleukin-2 on the manifestations of lepromatous leprosy. J Exp Med. 1991;173:993–1006. [PMC free article: PMC2190819] [PubMed: 2007862]

Riddell SR , Watanabe KS , Goodrich JM . et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238–42. [PubMed: 1352912]

Teppler H , Kaplan G , Smith K . et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis. 1993;167:291–8. [PubMed: 8421163]

Teppler H , Kaplan G , Smith KA . et al. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J Exp Med. 1993;177:483–92. [PMC free article: PMC2190894] [PubMed: 8093894]

Wood R , Montoya JG , Kundu SK . et al. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis. 1993;167:519–25. [PubMed: 8095058]

Margolin KA , Rayner AA , Hawkins MJ . et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors. J Clin Oncol. 1989;7:486–98. [PubMed: 2647914]

Moser RP , Bruner JM , Grimm EA . Biological therapy of brain tumors. Cancer Bull. 1991;43:117–26.

Sznol M, Hawkins MJ. Interleukin-2 in malignancies other than melanoma and renal cell carcinoma. In: Atkins MB, Mier JW, editors. Therapeutic applications of IL-2. New York: Marcel Dekker; 1993. p. 177.

Hayes RL . The cellular immunotherapy of primary brain tumors. Rev Neurol. 1992;148:454–66. [PubMed: 1448666]

Wollenberg B , Kastenbauer, Mundl H , Schaumberg J . Gene therapy—phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther. 1999;10:141–7. [PubMed: 10022539]

Foa R , Meloni G , Tosti S . et al. Treatment of anti myeloid leukemia patients with recombinant interleukin-2: a pilot study. Br J Haematol. 1991;77:491–6. [PubMed: 2025574]

Maraninchi D , Blaise D , Viens P . et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 1991;78:2182–7. [PubMed: 1932739]

Benyunes MC, Fefer A. IL-2 in the treatment of hematologic malignancies. In: Atkins MB, Mier JW, editors Therapeutic applications of Interleukin. New York: Marcel Dekker; 1993. p. 163-75.

Fefer A, Benyunes MC. Interleukin-2 as consolidative immunotherapy: clinical follow-up of patients treated with autologous bone marrow transplantation/interleukin-2 or interleukin-2/lymphokine-activated killer for acute myeloid leukemia 52. In: Spitzer TR, Mazumder A, editors. Immunotherapy and bone marrow transplantation. Mount Kisco (NY): Futura; 1995. p. 111-20.

Sykes M , Harty MW , Szot GL . et al. IL-2 inhibits graft-versus-host-disease-promoting activity of CD41 cells while preserving CD4- and CD8-mediated graft-vs-leukemia effects. Blood. 1994;83:2560–9. [PubMed: 7909457]

Atkins MB , Lotze MT , Dutcher JP . et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16. [PubMed: 10561265]

Fiedler W , Zeller W , Peimann C-J . et al. A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer. Klin Wochenschr. 1991;69:261–8. [PubMed: 1903822]

Weiss GR , Margolin KA , Aronson FR . et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol. 1992;10:275–81. [PubMed: 1732429]

Roberts AB , Sporn MB . Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors. 1993;8:1–9. [PubMed: 8448037]

Rosenberg SA , Packard BS , Aebersold PM . et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676–80. [PubMed: 3264384]

Siegel JP , Puri RK . Interleukin-2 toxicity. J Clin Oncol. 1991;9:694–704. [PubMed: 2066765]

Margolin K. The clinical toxicities of high-dose interleukin-2. In: Atkins MB, Mier JW, editors. Therapeutic applications of Interleukin-2. New York: Marcel Dekker; 1993. p. 331-62.

White RL , Schwartzentruber DJ , Guleria A . et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer. 1994;74:3212–22. [PubMed: 7982185]

Kammula US , White DE , Rosenberg SA . Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797–805. [PubMed: 9708948]

Heaton K , Ju G , Grimm EA . Human interleukin-2 analogs that preferentially bind the intermediate-affinity IL-2 receptor lead to reduced secondary cytokine secretion. Cancer Res. 1993;53:2597–602. [PubMed: 8495422]

Kobayashi M , Fitz L , Ryan M . et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827–45. [PMC free article: PMC2189443] [PubMed: 2504877]

Stern AS , Podlaski FJ , Hulmes JD . et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A. 1990;87:6808–12. [PMC free article: PMC54627] [PubMed: 2204066]

Trinchieri G . Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008–27. [PubMed: 7994020]

Merberg D , Wolf S , Clark S . Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today. 1992;13:77–8. [PubMed: 1374259]

Chizzonite R , Truitt T , Desai B . et al. IL-12 receptor: I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol. 1992;148:3117–24. [PubMed: 1578138]

Jacobsen SEW , Veiby OP , Smeland EB . Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med. 1993;178:413–18. [PMC free article: PMC2191103] [PubMed: 7688022]

Chan SH , Kobayashi M , Santoli D . et al. Mechanism of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). J Immunol. 1992;148:92–8. [PubMed: 1345792]

Chan SH , Perussia B , Gupta JW . et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869–79. [PMC free article: PMC2190821] [PubMed: 1672545]

Naume B , Gately M , Espevik TA . A comparative study of IL-12 (cytotoxic lymphocyte maturation factor), IL-12, and IL-7 induced effects on immunomagnetically purified CD561 NK cells. J Immunol. 1992;148:2429–36. [PubMed: 1373169]

Naume B , Gately MK , Desai BB . et al. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine. 1993;5:38–46. [PubMed: 8097934]

Mehrotra PT , Wu D , Crim JA . et al. Effects of IL-12 on the generation of cytotoxic activity in human CD81 T lymphocytes. J Immunol. 1993;151:2444–52. [PubMed: 8103066]

Robertson MJ , Soiffer RJ , Wolf SF . et al. Response of human natural killer cells to natural killer cell stimulatory factor: cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992;175:779–88. [PMC free article: PMC2119162] [PubMed: 1346796]

Del Prete GF , DeCarli M , Mastromauro C . et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest. 1991;88:346–50. [PMC free article: PMC296040] [PubMed: 1829097]

Golab J , Zagozdzon R . Antitumor effects of interleukin-12 in pre-clinical and early clinical studies [review] Int J Mol Med. 1999;3:537–44. [PubMed: 10202188]

Chougnet C , Shearer GM . Potential clinical applications of interleukin-12. Curr Opin Hematol. 1996;3:216–22. [PubMed: 9372079]

Freedman RS , Lenzi R , Kudelka AP . et al. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther. 1998;4:121–40. [PubMed: 9681251]

Loetscher H , Steinmetz M , Lesslauer W . Tumor necrosis factor: receptors and inhibitors. Cancer Cells. 1991;3:221–6. [PubMed: 1654969]

Goodwin RG , Anderson D , Jerzy R . et al. Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol Cell Biol. 1991;11:3020–6. [PMC free article: PMC360136] [PubMed: 1645445]

Paul NL , Ruddle NH . Lymphotoxin. Annu Rev Immunol. 1988;6:407–38. [PubMed: 3289572]

Essner R , Rhoades K , McBride WH . et al. IL-4 downregulates IL-1 and TNF gene expression in human monocytes. J Immunol. 1989;142:3857–61. [PubMed: 2785566]

Asher A , Mule JJ , Reichert CM . et al. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;138:963–74. [PubMed: 3805720]

Balkwill FR , Lee A , Aldam G . et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 1986;46:3990–3. [PubMed: 2425938]

Salmon SE , Young L , Scuderi P . et al. Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay. J Clin Oncol. 1987;5:1816–21. [PubMed: 3119787]

Sugarman BJ , Aggarwal BB , Hass PE . et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943–5. [PubMed: 3933111]

Alexander RB , Nelson WG , Coffey DS . Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res. 1987;47:2403–6. [PubMed: 2436763]

Valenti M , Cimoli G , Parodi S . et al. Potentiation of tumor necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer. 1993;29A:1157–61. [PubMed: 8518027]

Burgers JK , Marshall FF , Isaacs JT . Enhanced antitumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model. J Urol. 1989;142:160–4. [PubMed: 2733097]

Krosnick JA , Mule JJ , McIntosh JK , Rosenberg SA . Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 1989;49:3729–33. [PubMed: 2736513]

Mueller H . Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci. 1998;54:1291–8. [PubMed: 9893706]

Bannerji R , Arroyo CD , Cordon-Cordo C . et al. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol. 1994;152:2324–32. [PubMed: 7907636]

Zimmerman RJ , Gauny S , Chan A , Landry P . et al. Sequence dependence of administration of human recombinant tumor necrosis factor and interleukin-2 in murine tumor therapy. J Natl Cancer Inst. 1989;81:227–31. [PubMed: 2783463]

Negrier MS , Pourreau CN , Palmer PA . et al. Phase-I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J Immunother. 1992;11:93–102. [PubMed: 1571336]

Schiller JH , Witt PL , Storer B . et al. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer. 1992;69:562–71. [PubMed: 1728387]

Smith JW , Urba WJ , Clark JW . et al. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J Immunother. 1991;10:355–62. [PubMed: 1790143]

Orr D , Oldham R , Lewis M . et al. Phase I study of the sequenced administration of etoposide (VP-16) and recombinant tumor necrosis factor (rTNF; Cetus) in patients with advanced malignancy. Proc Am Soc Clin Oncol. 1989;8:A741.

Jones AL , O'Brien MER , Lorentzos A . et al. A randomized phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma. Cancer Chemother Pharmacol. 1992;30:73–6. [PubMed: 1586984]

Lejeune FJ . High-dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer. 1995;31A:1009–16. [PubMed: 7646901]

Fraker DL, Alexander RH. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. Adv Oncol 1994;179-92. [PubMed: 8206489]

Fraker DL , Alexander RH , Andrich M , Rosenberg SA . Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am. 1995;1:1081–4442. [PubMed: 9166465]

Fraker DL , Alexander RH , Andrich M , Rosenberg SA . Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol. 1996;14:479–89. [PubMed: 8636761]

Thom AK , Alexander RH , Andrich MP . et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma, and melphalan. J Clin Oncol. 1995;13:264–73. [PubMed: 7799030]

Lienard D , Ewalenko P , Delmotti JJ . et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60. [PubMed: 1727926]

Manusama ER , Durante NMC , Marquet RL . et al. Isolated limb perfusion with tumor necrosis factors and melphalan for fibrosarcoma in brown Norway rats. Proc Am Assoc Cancer Res. 1994;35:524.

Hoekstra HJ , Naujocks T , Schrafford Koops H . et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: technique and results. Reg Cancer Treat. 1992;4:301–4.

Renard N , Lienard D , Lespagnard L . et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha. Int J Cancer. 1994;57:656–63. [PubMed: 8194873]

Dinarello CA . Biology of interleukin 1. FASEB J. 1988;2:108–15. [PubMed: 3277884]

Dinarello CA . Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627–52. [PubMed: 1826616]

March CJ , Mosley B , Larsen A . et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985;315:641–7. [PubMed: 2989698]

Braunschweiger PG , Johnson CS , Kumar N . et al. Antitumor effects of recombinant human interleukin-1 alpha on RIF-1 and Panc02 solid tumors. Cancer Res. 1988;48:6011–6. [PubMed: 3262418]

Bagby GC Jr, Dinnarello CA , Wallace P . et al. Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest. 1986;78:1316–23. [PMC free article: PMC423824] [PubMed: 3490494]

Mule JJ , Marcus SG , Yang JC . et al. Clinical applications of IL-6 in cancer therapy. Res Immuol. 1992;143:777–9. [PubMed: 1439156]

Zucali JR , Dinarello CA , Oblon DJ . et al. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E₂. J Clin Invest. 1986;77:1857–63. [PMC free article: PMC370544] [PubMed: 3486886]

Nakamura S , Kashimoto S , Kajikawa F . et al. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice. Cancer Res. 1991;51:215–21. [PubMed: 1899039]

Usui N , Mimnaugh EG , Sinha BK . A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells. Cancer Res. 1991;51:769–74. [PubMed: 1824825]

Smith JW II, Longo DL , Alvord WG . et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. 1993;328:756–61. [PubMed: 8437596]

Veltri S , Smith JW . Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Oncologist. 1996;1:190–200. [PubMed: 10387988]

Ishibashi T , Kimura H , Shikama Y . et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74:1241–4. [PubMed: 2788464]

Matsuda T , Hirano T . Interleukin-6 (IL-6). Biotherapy. 1990;2:363–73. [PubMed: 2268501]

Van Snick J . Interleukin-6: an overview. Annu Rev Immun. 1990;8:253–78. [PubMed: 2188664]

Bajorin DF , Jakubowski A , Cody B . et al. Recombinant macrophage colony stimulating factor: a phase I trial in patients with metastatic melanoma [abstract] Proc Am Soc Clin Oncol. 1990;9:183.

Gauldie J , Richards C , Harnish D . et al. Interferon B2/BSF-2 shares identity with monocyte-derived hepatocyte stimulating factor (HSF) and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987;84:7251–5. [PMC free article: PMC299269] [PubMed: 2444978]

Tosato G , Pike S . Interferon B2/interleukin-6 is a costimulant for human T lymphocytes. J Immunol. 1988;141:1556–62. [PubMed: 2842397]

Tosato G , Seamon KB , Goldman ND . et al. Monocyte-derived human B-cell growth factor identified as interferon-B₂ (BSF-3, IL-6). Science. 1988;239:502–4. [PubMed: 2829354]

Uyttenhove C , Coulie PG , Van Snick J . T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med. 1988;167:1417–27. [PMC free article: PMC2188915] [PubMed: 2965738]

Van Damme J , Opdenakker G , Simpson RJ . Identification of the human 26-kd protein, interferon beta-2 (IFN β2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin and tumor necrosis factor. J Exp Med. 1987;165:914–20. [PMC free article: PMC2188297] [PubMed: 3493322]

Tagga T , Hibi M , Hirata Y . et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer gp 130. Cell. 1989;58:573–81. [PubMed: 2788034]

Yanasaki K , Taga T , Hirata Y . et al. Cloning and expression of the human interleukin-6 (BSF-2/IFNB2) receptor. Science. 1988;241:825–8. [PubMed: 3136546]

Geiger T , Andus T , Klapproth J . et al. Induction of rat acute phase proteins by interleukin-6 in vivo. Eur J Immunol. 1988;18:717–21. [PubMed: 2454191]

Hirano T , Kishimoto T . Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSF p-2). Proc Natl Acad Sci U S A. 1985;82:5490–4. [PMC free article: PMC391148] [PubMed: 2410927]

Jilka RL , Hangoc G , Grasole G . et al. Increase osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88–91. [PubMed: 1621100]

Spangelo BL , Judd AM , Isakson PC . et al. Interleukin-6 stimulates anterior pituitary hormone release in vivo. Endocrinology. 1989;125:575–7. [PubMed: 2544414]

Weber J , Gunn H , Yang J . et al. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunotherapy. 1994;15:292–302. [PubMed: 7520334]

Weber J , Yang JC , Topalian SL . et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993;11:499–506. [PubMed: 7680375]

Schuler M , Peschel C , Schneller F . et al. Immunomodulator and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J Interferon Cytokine Res. 1996;16:903–10. [PubMed: 8938565]

Hart PH , Vitti DR , Burgess GA . et al. Potential anti-inflammatory effects of interleukin-4: suppression of human monocyte tumor necrosis factor alpha, interleukin-1, and prostaglandin E₂. Proc Natl Acad Sci U S A. 1989;86:3803–7. [PMC free article: PMC287229] [PubMed: 2786204]

Atkins MB , Vachino G , Tilg HJ . et al. Phase I evaluation of thrice daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol. 1992;10:1802–9. [PubMed: 1403061]

Gilleece MH , Scarffe JH , Ghosh A . et al. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections: phase I dose toxicity trial. Br J Cancer. 1992;66:204–10. [PMC free article: PMC1977892] [PubMed: 1637669]

Prendiville J , Thatcher N , Lind M . et al. Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer: phase I toxicity study and pharmacokinetic analysis. Eur J Cancer. 1993;29A:1700–7. [PubMed: 8398297]

Margolin R , Aronson FR , Sznol M . et al. Phase II studies of recombinant human IL-4 in advanced renal cancer and malignant melanoma. J Immunother. 1994;15:147–53. [PubMed: 8136948]

Vokes EE , Figlin R , Hochster H . et al. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. Cancer J Sci Am. 1998;4:46–51. [PubMed: 9467046]

Ralph P , Sampson-Johannes A . Macrophage growth and stimulating factor, M-CSF. Prog Clin Biol Res. 1990;338:43–63. [PubMed: 2189140]

Sherr CJ . Regulation of mononuclear phagocyte proliferation by colony-stimulating factor-1. Int J Cell Cloning. 1990;8:46–60. [PubMed: 2157778]

Sherr CJ . Colony-stimulating factor-1 receptor. Blood. 1990;75:1–12. [PubMed: 2153029]

Bock SN , Cameron RB , Kragel P . et al. Biologic and antitumor effects of recombinant human macrophage colony-stimulating factor in mice. Cancer Res. 1991;51:264–65. [PubMed: 2021943]

Munn DH , Cheung N-KV . Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony stimulating factor. J Exp Med. 1990;172:231–7. [PMC free article: PMC2188164] [PubMed: 2193096]

Thomassen MJ , Barna BP , Weidman HP . et al. Modulation of human alveolar macrophage tumoricidal activity by recombinant macrophage colony-stimulating factor. J Biol Response Mod. 1990;9:87–91. [PubMed: 2156955]

Wing EJ , Waheed A , Shadduck RK . et al. Effect of colony-stimulating factor on murine macrophages. Induction of antitumor activity. J Clin Invest. 1982;69:270–6. [PMC free article: PMC370975] [PubMed: 6799546]

Hume DA , Donahue RE , Fidler IJ . The therapeutic effect of human recombinant macrophage colony-stimulating factor in experimental murine metastatic melanoma. Lymphokine Res. 1989;8:69–77. [PubMed: 2654493]

Munn DH , Cheung NK . Antibody dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony stimulating factor. J Exp Med. 1989;170:511–26. [PMC free article: PMC2189400] [PubMed: 2526848]

Nemunatitis J . A comparative review of colony-stimulating factors. Drugs. 1997;54:709–29. [PubMed: 9360058]

Cole DJ , Sanda MG , Yang JC . et al. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J Natl Cancer Inst. 1994;86:39–45. [PubMed: 8271281]

Redman BG , Flaherty L , Chou TH . et al. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. J Immunother. 1992;12:50–54. [PubMed: 1637782]

Sanda MG , Yang JC , Topalian SL . et al. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J Clin Oncol. 1992;10:1643–9. [PubMed: 1403042]

Zamkoff DW , Hudson J , Groves ES . et al. A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy. J Immunother. 1992;11:103–10. [PubMed: 1571332]

Lee M-T , Warren MK . CSF-induced resistance to viral infection in murine macrophages. J Immunol. 1987;138:3019–22. [PubMed: 3033081]

Masaoka T , Shibata H , Ohno R . et al. Double blind test of human urinary macrophage colony stimulating factor for allogeneic and syngeneic bone marrow transplantation: effectiveness of treatment and 2-year follow-up for relapse of leukemia. Br J Haematol. 1990;76:501–5. [PubMed: 2265113]

Howard M , Farrar J , Hilfiker H . et al. Identification of T-cell-derived B-cell growth factor distinct from interleukin-4. J Exp Med. 1982;155:914–23. [PMC free article: PMC2186613] [PubMed: 6977612]

Viera P , De Waal Malefyt R , Dang MN . et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A. 1991;88:1172–6. [PMC free article: PMC50979] [PubMed: 1847510]

Gerard C , Bruyns C , Marchant A . et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 1993;177:547–50. [PMC free article: PMC2190913] [PubMed: 8426124]

Howard M , Muchamuel T , Andrade S . et al. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med. 1993;177:1205–8. [PMC free article: PMC2190971] [PubMed: 8459215]

Gorczynski RM , Wojcik D . A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1 and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion. J Immunol. 1994;152:2011–9. [PubMed: 7907109]

Chernoff AE , Granowitz EV , Shapiro L . et al. A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol. 1995;154:5492–9. [PubMed: 7730651]

Huhn RD , Pennline K , Radwanski E . et al. Effects of single intravenous doses of recombinant human interleukinl-10 on subsets of circulating leukocytes in humans. Immunopharmacology. 1999;41:109–17. [PubMed: 10102792]

Vuoristo M , Jantunen I , Pyrhonen S . et al. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma. Eur J Cancer. 1994;30A:530–2. [PubMed: 8018415]

Minty A , Chalon P , Derocq M . et al. Interleukin 13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248–50. [PubMed: 8096327]

Giri JG , Ahdieh M , Eisenman J . et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822–30. [PMC free article: PMC395163] [PubMed: 8026467]

Grabstein KH , Eisenman J , Shanebeck K . et al. Cloning of a T cell growth factor that interacts with the B chain of the interleukin-2 receptor. Science. 1994;264:965–8. [PubMed: 8178155]

Carson WE , Giri JG , Lindemann MJ . et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395–403. [PMC free article: PMC2191697] [PubMed: 7523571]

Rouvier E , Luciani MF , Mattei MG . et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150:5445–56. [PubMed: 8390535]

Aggarwal S , Gurney AL . IL-17: prototype member of an emerging cytokine family. J Leuk Biol. 2002;71:1–8. [PubMed: 11781375]

Chaubaud M , Durand JM , Buchs N . et al. Human interleukin-17: a T-cell derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963–70. [PubMed: 10323452]

Okamura H , Tsutsui H , Komatsu T . et al. Cloning of a new cytokine that induces IFN-α production by T cells. Nature. 1995;378:88–91. [PubMed: 7477296]

Swain SL . Interleukin 18: tipping the balance towards a T helper cell 1 response. J Exp Med. 2001;194:F11–4. [PMC free article: PMC2193473] [PubMed: 11489958]

Gallagher G , Dickensheets H , Eskdale J . et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immunol. 2000;1:442–50. [PubMed: 11196675]

Blumberg H , Conklin D , Xu WF . et al. Interleukin 20: Discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9–19. [PubMed: 11163236]

Dumoutier L , Leemans C , Lejeune D . et al. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167:3545–9. [PubMed: 11564763]

Dumoutier L , Louahed J , Renauld JC . Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000;164:1814–9. [PubMed: 10657629]

Kotenko SV , Izotova LS , Mirochnitchenko OV . et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001;276:2725–32. [PubMed: 11035029]

Jiang H , Lin JJ , Su ZZ . et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995;11:2477–86. [PubMed: 8545104]

Wang M , Tan Z , Zhang R . et al. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem. 2002;277:7341–7. [PubMed: 11706020]

Ekmekcioglu S , Ellerhorst J , Mhashilkar AM . et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001;94:54–9. [PubMed: 11668478]

Ellerhorst JA , Prieto VG , Ekmekcioglu S . et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002;20:1069–74. [PubMed: 11844832]

Fort MM , Cheung J , Yen D . et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985–95. [PubMed: 11754819]